Serotype Distribution in Hospitalized Adult With Pneumococcal Community Acquired Pneumonia in France

Institut National de la Santé Et de la Recherche Médicale, France1,017 enrolled

Overview

CAP'Hospi is an observational, multicentric study in France which primary objective is to describe the proportion of Community Acquired Pneumonia due to serotypes included in PCV20 among adults hospitalized for CAP

Study Type

OBSERVATIONAL

Enrollment

1,017

Conditions

Pneumonia Pneumococcal Infections Community-acquired Pneumonia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Adults 18 years of age or older 2. Admission to hospital for at least 24 hours 3. Suspicion of community-acquired pneumonia at admission defined as the association of: Radiologic findings consistent with pneumonia (eg, pleural effusion, increased pulmonary density due to infection and/or alveolar infiltrates \[multilobar, lobar, or segmental\] containing air bronchograms), AND The presence of ≥2 of the following signs or symptoms: Fever (oral temperature \>38°C or tympanic temperature \>38.5°C) in the 24 hours preceding admission; Hypothermia (\<35.5°C measured by a healthcare provider) in the 24 hours preceding admission ; Chills or rigors ; Pleuritic chest pain ; New or worsening cough ; Sputum production ; Dyspnea (shortness of breath); Tachypnea (respiratory rate \>20/min) ; Malaise ; Abnormal auscultatory findings suggestive of pneumonia (rales or evidence of pulmonary consolidation) 4. Written informed consent from the patient Exclusion Criteria: 1. Suspicion of tuberculosis 2. Individuals placed under judicial protection 3. Individuals who refuse the transfer of biological samples to the USA 4. Patient developing signs and symptoms of pneumonia after having been hospitalized for 48 hours or more 5. Pregnancy

Locations (5)

CHU Rennes

Rennes, Brittany Region, France

Hopital de la Croix Rousse, Hospices Civils de Lyon

Lyon, France

Hôpital Cochin

Paris, France

Hôpital Bichat

Paris, France

CHU de Saint-Etienne

Outcomes

Primary Outcomes

proportions of S. pneumoniae serotypes included in PCV20

The proportion will be determined by UAD assay and/or culture from any sites overall and by age and risk group among adults hospitalized with CAP

Time frame: 2 years

Secondary Outcomes

proportion of serotypes of S. pneumoniae by group

Among adults hospitalized for all-cause CAP or pneumococcal CAP the proportion of serotypes of S. pneumoniae grouped by serotypes included into pneumococcal vaccines and individual serotypes, by age and risk group

Time frame: 2 years

Patients hospital trajectories

The proportion of patients who died from any cause, the proportion of patients requiring mechanical ventilation within the first 30 days of hospitalization, the proportion of patients who required transfer to ICU within the first 30 days of hospitalization, the length of ICU-stay, the length of hospital-stay, the proportion of patients who required hospital re-admission

Time frame: 2 years

Patients hospital stay by serotype groups

Time frame: 2 years

Prevalence of different bacterial and viral causes of hospitalized CAP

description of the proportion of bacteria and virus attributable to each patients

Time frame: 2 years

The proportion of patients with a severe CAP

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.